Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04742556
Status:
COMPLETED
Last Update Posted:
2022-11-14
First Post:
2021-02-03
Brief Title:
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer NRASKRAS Mutation Positive
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
A Phase I Open-label Trial of BI 3011441 in Japanese Patients With NRASKRAS Mutation Positive Advanced Unresectable or Metastatic Refractory Solid Tumours
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is open to Japanese adults with different types of advanced cancer that are positive for NRASKRAS mutations This is a study in people for whom previous treatment was not successful or no standard treatment exists
The purpose of this study is to find the highest dose of BI 3011441 that Japanese people with advanced cancer can tolerate BI 3011441 is a medicine that may turn off a signal by NRASKRAS that makes tumours grow
Participants take BI 3011441 as capsules once a day Participants can stay in the study as long as they benefit from treatment and can tolerate it The doctors collect information on any health problems of the participants
The purpose of this study is to find the highest dose of BI 3011441 that Japanese people with advanced cancer can tolerate BI 3011441 is a medicine that may turn off a signal by NRASKRAS that makes tumours grow
Participants take BI 3011441 as capsules once a day Participants can stay in the study as long as they benefit from treatment and can tolerate it The doctors collect information on any health problems of the participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None